Illumina TruSight Oncology 500
Illumina has launched TruSight Oncology 500 (TSO 500), a pan-cancer assay to identify known and emerging biomarkers. The assay, which is for research use only and will start shipping in the first quarter of 2019, uses both DNA and RNA from tumor samples to identify somatic variants, including small variants, gene fusions, and splice variants. It can also measure tumor mutational burden and microsatellite instability. The assay covers a large number of genes as well as 1.94 megabases of the genome to measure TMB.